SV

Street Verdict

Analyst Scorecard

AARTIDRUGS · NSE

Aarti Drugs Limited

₹484.5

-2.89% (-₹14.4)

Prev. close

₹498.9

Volume

2,92,093

Delivery %

36.7%

As of

20 Nov 2026

Price history

₹484.5+₹71.7 (+17.37%) · 3M
18 Aug 2026 → 20 Nov 2026
38040042044046048050018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Rashesh Chandrakant Gogri

Headquarters

Mumbai

Employees

1,355

Key stats

Market cap

₹4,174.23 Cr

P/E ratio (TTM)

22.4

Dividend yield

0.43%

EPS (TTM)

₹20.46

Beta (1Y · daily vs NIFTY 50)

0.76

Beta (5Y · monthly vs NIFTY 50)

0.95

Shares float

3.54 Cr

EPS · quarter ended Jun 2026

₹5.49

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%5%10%15%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

010203040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0123₹-200%0%200%400%17 Feb 2003 Nov 2009 Feb 2208 Feb 2306 Feb 2404 Feb 2509 Feb 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,154.78 Cr₹2,488.65 Cr₹2,716.05 Cr₹2,528.58 Cr₹2,387.03 Cr₹2,565.31 Cr
EBITDA
₹441.85 Cr₹340.76 Cr₹307.79 Cr₹320.50 Cr₹303.42 Cr₹311.58 Cr
₹280.00 Cr₹205.00 Cr₹166.31 Cr₹171.42 Cr₹168.16 Cr₹194.92 Cr
Diluted EPS
₹30.09₹22.12₹17.97₹18.56₹18.35₹21.36

09 · Balance Sheet — as filed

Annual

Line itemFY24FY25FY26
₹1,111.64 Cr₹1,236.32 Cr₹1,347.49 Cr
Inventories
₹485.89 Cr₹472.93 Cr₹490.78 Cr
(0) Trade Receivable
₹704.55 Cr₹751.18 Cr₹829.87 Cr
(ii) Cash and Cash Equivalents
₹6.74 Cr₹4.58 Cr₹7.27 Cr
(iii) Bank Balances Other than (ii) above
₹2.69 Cr₹2.98 Cr₹1.54 Cr
(iv) Loan
₹23.66 L₹75.77 L₹70.30 L
(v) Other Financial Assets
₹11.34 Cr₹15.05 Cr₹15.47 Cr
₹1,320.72 Cr₹1,338.36 Cr₹1,467.77 Cr
TOTAL ASSETS
₹2,432.36 Cr₹2,574.68 Cr₹2,815.26 Cr
₹1,281.95 Cr₹1,369.34 Cr₹1,549.23 Cr
₹1,281.55 Cr₹1,369.00 Cr₹1,548.86 Cr
Non- Controlling Interests
₹40.58 L₹34.43 L₹36.46 L
(i) Borrowings
₹275.33 Cr₹284.00 Cr₹256.87 Cr
(ii) Lease Liabilities
₹91.40 L₹1.65 Cr₹85.99 L
(ii) Other financial liabilities
₹16.99 L₹16.01 L₹23.16 L
₹354.86 Cr₹368.37 Cr₹343.78 Cr
(i) Borrowings
₹287.09 Cr₹328.24 Cr₹317.96 Cr
(ii) Lease Liabilities
₹94.96 L₹1.18 Cr₹94.65 L
Dues of micro enterprises and small enterprises
₹13.98 Cr——
Dues of creditors other micro enterprises and small enterprises
₹411.51 Cr——
(a) Total outstanding dues of micro and small enterprises
—₹11.80 Cr₹24.09 Cr
(b) Total outstanding dues of other than micro and small enterprises
—₹404.34 Cr₹453.79 Cr
(iv) Other Financial Liabilities
₹26.33 Cr₹20.23 Cr₹22.80 Cr
—₹836.97 Cr₹922.26 Cr
TOTAL EQUITY AND LIABILITIES
₹2,432.36 Cr₹2,574.68 Cr₹2,815.26 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2.04 Cr₹12.80 Cr₹-14.11 Cr₹-76.07 L₹-2.17 Cr₹2.69 Cr
₹154.95 Cr₹70.41 Cr₹133.32 Cr₹358.92 Cr₹244.58 Cr₹253.54 Cr
₹-71.78 Cr₹-149.64 Cr₹-163.97 Cr₹-223.65 Cr₹-164.63 Cr₹-173.41 Cr
₹-81.13 Cr₹92.03 Cr₹16.54 Cr₹-136.03 Cr₹-82.12 Cr₹-77.44 Cr
Opening Cash and Cash Equivalents
₹6.77 Cr₹8.81 Cr₹21.61 Cr₹7.50 Cr₹6.74 Cr₹4.58 Cr
Closing Cash and Cash Equivalents
₹8.81 Cr₹21.61 Cr₹7.50 Cr₹6.74 Cr₹4.58 Cr₹7.27 Cr
₹8.81 Cr₹21.61 Cr₹7.50 Cr₹6.74 Cr——
Balance with Banks
₹6.96 Cr₹20.84 Cr₹6.34 Cr₹4.43 Cr——
Cash in Hand
₹29.95 L₹24.33 L₹28.24 L₹26.17 L——
Cheques in Hand
₹1.55 Cr₹52.65 L₹88.01 L₹2.05 Cr——

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25–Mar 26(2Q)Jun 26
Promoter60.12%59.99%59.83%59.98%59.77%59.66%59.58%58.70%58.56%57.47%57.13%55.67%55.64%55.38%55.48%55.22%54.72%55.03%54.43%
Public39.88%40.01%40.17%40.02%40.23%40.34%40.42%41.30%41.44%42.53%42.87%44.33%44.36%44.62%44.52%44.78%45.28%44.97%45.57%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Aarti Drugs Limited₹4,172.86 Cr₹466.321.82.6912.6%0.37+6.4%-7.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Index membership

1 index

AARTIDRUGS

Aarti Drugs Share Price Rises 12.25%: Price and Fundamentals

Aarti Drugs Ltd. shares jumped 12.25%, rising to Rs 452.8 from Rs 403.4, with a market cap of Rs 3,465.52 crore. The gain follows a sharp intraday rally, while the company’s P/E of 19.26x and ROE of 13.36% place it below sector valuation averages but above peer median returns.

2 days ago·Read at Univest
AARTIDRUGS

Pharma sector stocks today, November 17: Aarti Drugs jumps 1.60%, Wockhardt up 1.43%, Zydus Life rises 0.98%

Aarti Drugs rose 1.60% to Rs 509.25, leading gains among pharma stocks on Tuesday, November 17, 2026. The broader market was positive, with the Nifty 50 up 0.27% to 25,359.80, while 11 of 21 pharma shares advanced and 10 fell, indicating mixed sector momentum.